Want to see NVAX full AI Analyst Report?
NVAX Stock Chart & Stats
$8.84
-$1.22(-11.32%)
At close: 4:00 PM EST
$8.84
-$1.22(-11.32%)
Day’s Range― - ―
52-Week Range$6.20 - $11.97
Previous CloseN/A
Volume4.15M
Average Volume (3M)3.87M
Market Cap
$1.30B
Enterprise Value$833.79
Total Cash (Recent Filing)$790.33M
Total Debt (Recent Filing)$295.06M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 12, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding164,438,130
10 Day Avg. Volume3,200,905
30 Day Avg. Volume3,868,457
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.33Price Target Upside28.21% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$409.97M
Bulls Say, Bears Say
Bulls Say
Partnership Network & LicensingA broad set of partnerships and MTAs with top pharma (including a Pfizer upfront and Sanofi collaboration) diversifies commercialization pathways, creates multiple milestone/royalty streams, and outsources late‑stage risks — a durable route to revenue without sole reliance on in‑house sales.
Partner-Related Revenue MomentumRapid partner‑driven revenue growth shows the company can monetize its Matrix‑M and manufacturing capabilities through supply and licensing, generating non‑dilutive cash and higher‑margin flows that can support operations even as direct product sales remain modest.
Cash Runway From Non‑Dilutive SourcesA sizable cash and receivables balance plus recent nondilutive inflows materially extend runway, lowering immediate refinancing pressure and giving management time to convert MTAs, advance prioritized R&D, and execute cost reductions to reach sustainable profitability.
Bears Say
Balance Sheet WeaknessPersistently negative shareholders' equity signals structural balance sheet weakness that limits financial flexibility, raises refinancing and dilution risk, and can constrain strategic options if revenue or partner payments slip.
Weak Cash GenerationSustained negative operating and free cash flow imply the business is burning cash rather than consistently generating it; this elevates dependency on partner payments or financing and makes long‑term self‑funding of R&D and launches uncertain without execution.
Reliance On Partner Conversions & Low Direct SalesLow direct product sales combined with uncertain MTA‑to‑license conversion timelines mean future revenue and milestone realization depend heavily on partners' decisions and execution, creating timing risk and potential volatility in cash receipts over the medium term.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $6.20 and its highest was $11.97 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.30B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 12, 2026 which is in 19 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 06, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.182.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.4.
How many shares outstanding does Novavax have?
Novavax has 164,438,130 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went up 15.556%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$11.33 (28.21% Upside)
$11.33 (28.21% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.32%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Stock 12 Month Forecast
Average Price Target
$11.33
▲(28.21% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―
Ownership Overview
0.58% Insiders
12.71% Mutual Funds
0.01% Other Institutional Investors
66.01% Public Companies and
Individual Investors